| Aplastic Anemia and MDS International Foundation

March for Marrow 5K Run & Walk Washington, DC

Get involved and give back by joining the March for Marrow 5K Run & Walk Washington, DC!  REGISTER NOW.

The event will be held on Saturday, December 10 at East Potomac Park/Hains Point in Washington, DC.  The 5K Run will begin at 7:00 am.  In addition to the 5K, the March for Marrow Walk will also be held at 7:30 am.

Event Date: 
Sat, 12/10/2016 -
6:00am to 9:15am
Community Event Type: 

Pro-inflammatory proteins S100A9 and TNFα suppress erythropoietin elaboration in myelodysplastic syndromes

Author(s): 
Cluzeau T, McGraw KL, Irvine B, Masala E, Ades L, Basiorka AA, Maciejewski JP, Auberger P, Wei S, Fenaux P, Santini V, List A
Primary Author: 
Cluzeau T
Journal Title: 
Haematologica
Original Publication Date: 
Oct 2017

Accumulating evidence implicates innate immune activation in the pathobiology of

Bone Marrow Diseases: 

Confronting Challenges in Finding Matches for Multiracial Patients

Person's Name: 
Krissy Kobata

34-year-old Krissy Kobata is a passionate patient and advocate/activist. Diagnosed in 2008 with MDS, she’s the epitome of resilience as she has waited for years to find a matched donor. She has devoted this time to helping other patients by enlarging the Be The Match® bone marrow registry.

Bone Marrow Diseases: 

Kansas City

Thank you for attending the 2017 Patient and Family Conference in Kansas City, MO.

Thank you for attending the 2017 Patient and Family Conference in Kansas City, MO.
Event Date: 
Sat, 10/14/2017 -
7:30am to 1:30pm
Conference Event Type: 

Haploidentical transplant in patients with myelodysplastic syndrome

Author(s): 
Marie Robin, Raphael Porcher, Fabio Ciceri, Maria Teresa van Lint, Stella Santarone, Gerhard Ehninger, Didier Blaise, Zafer Güllbas, Soledad Gonzáles Muñiz, Mauricette Michallet, Andrea Velardi, Linda Koster, Johan Maertens, Jorge Sierra
Primary Author: 
Marie Robin
Journal Title: 
Blood Advances
Original Publication Date: 
Jul 2017

The only curative treatment in patients with intermediate or high-risk myelodysplastic syndrome (MDS) is allogeneic hematopoietic stem cell transplantation (HSCT), which usually results in a long-term, disease-free survival rate of between 30% and 50%, depending on the disease risk and the type of donor. In patients without an HLA-matched sibling donor, a family haploidentical donor is an alternative option.

Bone Marrow Diseases: 

Gemtuzumab Receives New FDA Approval for Acute Myeloid Leukemia

Author(s): 
NCI Staff
Primary Author: 
NCI Staff
Journal Title: 
NIHNCI
Original Publication Date: 
Sep 2017

On September 1, the Food and Drug Administration (FDA) approved gemtuzumab ozogamicin (Mylotarg™) for some patients with acute myeloid leukemia (AML).

The approval covers the use of gemtuzumab in adults with newly diagnosed AML that expresses a protein called CD33 (CD33-positive AML). The approval also covers the treatment of patients aged 2 and older with CD33-positive AML who have experienced a relapse or whose disease has not responded to initial treatment.

Bone Marrow Diseases: